Active	Status	Sponsor type	Region	Phase	Filter
1 Active 3 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
limertinib (ASK120067) / Aosaikang Pharma
NCT04143607: ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC	Active, not recruiting	3	337	RoW	ASK120067, Placebo Gefitinib 250 mg, Placebo Iressa 250 mg, Gefitinib, Placebo ASK120067	Jiangsu Aosaikang Pharmaceutical Co., Ltd.	Locally Advanced or Metastatic NSCLC	03/24	09/26